ImmuCell

ImmuCell Capital Intensity

The Capital Intensity Ratio of ImmuCell (ICCC) as of Oct 27, 2026 is 153.86 %. In the previous year, Capital Intensity Ratio was 170.23 % — a change of -9.62% (lower).

Capital Intensity

153.86 %

YoY

-9.62%

Last updated:

Capital Intensity Ratio of ImmuCell is 2025 153.86 % . Capital Intensity Ratio of ImmuCell was 2024 170.23 % . It decreases by -9.62% lower compared to the previous year.

The ImmuCell Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
297.93 USD
Jan 1, 2019
281.95 USD
Jan 1, 2020
263.00 USD
Jan 1, 2021
231.08 USD
Jan 1, 2022
241.60 USD
Jan 1, 2023
250.74 USD
Jan 1, 2024
170.23 USD
Jan 1, 2025
153.86 USD
The ImmuCell Capital Intensity history
YEARCapital IntensityYoY
153.86 %-9.62%
170.23 %-32.11%
250.74 %+3.78%
241.60 %+4.56%
231.08 %-12.14%
263.00 %-6.72%
281.95 %-5.37%
297.93 %-9.39%
328.82 %+27.07%
258.77 %+81.29%
142.74 %-1.88%
145.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Capital Intensity Ratio of ImmuCell is 153.86 % in 2025.

Capital Intensity Ratio of ImmuCell changed from 170.23 % to 153.86 %, representing a -9.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio ImmuCell since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's ImmuCell with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ImmuCell

All Key Metrics — ImmuCell